Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

SARS-CoV-2 vaccination of convalescents boosts neutralization capacity against SARS-CoV-2 Delta and Omicron that can be predicted by anti-S antibody concentrations in serological assays

Alina Seidel, Bernd Jahrsdörfer, View ORCID ProfileSixten Körper, View ORCID ProfileDan Albers, Pascal von Maltitz, Rebecca Müller, Ramin Lotfi, Patrick Wuchter, Harald Klüter, View ORCID ProfileMichael Schmidt, Jan Münch, Hubert Schrezenmeier
doi: https://doi.org/10.1101/2022.01.17.22269201
Alina Seidel
1Institute of Molecular Virology, Ulm University Medical Center, 89081, Ulm, German
MSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bernd Jahrsdörfer
2German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen, Institute and Institute for Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service Baden- Württemberg-Hessen and University Hospital Ulm; and Institute of Transfusion Medicine, University of Ulm
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sixten Körper
2German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen, Institute and Institute for Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service Baden- Württemberg-Hessen and University Hospital Ulm; and Institute of Transfusion Medicine, University of Ulm
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sixten Körper
Dan Albers
1Institute of Molecular Virology, Ulm University Medical Center, 89081, Ulm, German
MSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Dan Albers
Pascal von Maltitz
1Institute of Molecular Virology, Ulm University Medical Center, 89081, Ulm, German
MSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rebecca Müller
3Institute of Transfusion and Immunology, German Red Cross Blood Transfusion Service Baden- Württemberg - Hessen, Medical Faculty Mannheim, Heidelberg University, Mannheim
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ramin Lotfi
2German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen, Institute and Institute for Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service Baden- Württemberg-Hessen and University Hospital Ulm; and Institute of Transfusion Medicine, University of Ulm
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrick Wuchter
3Institute of Transfusion and Immunology, German Red Cross Blood Transfusion Service Baden- Württemberg - Hessen, Medical Faculty Mannheim, Heidelberg University, Mannheim
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Harald Klüter
3Institute of Transfusion and Immunology, German Red Cross Blood Transfusion Service Baden- Württemberg - Hessen, Medical Faculty Mannheim, Heidelberg University, Mannheim
MD.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Schmidt
4Institute of Transfusion Medicine and Immunohematology, German Red Cross Blood Transfusion Service Baden- Württemberg – Hessen, Frankfurt, Germany
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Michael Schmidt
Jan Münch
1Institute of Molecular Virology, Ulm University Medical Center, 89081, Ulm, German
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hubert Schrezenmeier
2German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen, Institute and Institute for Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service Baden- Württemberg-Hessen and University Hospital Ulm; and Institute of Transfusion Medicine, University of Ulm
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: h.schrezenmeier{at}blutspende.de
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background Recent data on immune evasion of new SARS-CoV-2 variants raise concerns about antibody-based COVID-19 therapies. Therefore in this study the in-vitro neutralization capacity against SARS-CoV-2 variants Wuhan D614G, Delta and Omicron in sera of convalescent individuals with and without boost by vaccination was assessed.

Methods and Findings This in-vitro study included 66 individuals with a history of SARS-CoV-2 infection, divided into subgroups without (n=29) and with SARS-CoV-2 vaccination (n=37). We measured SARS-CoV-2 antibody concentrations by serological assays (anti-SARS-CoV-2-QuantiVac-ELISA (IgG) and Elecsys Anti-SARS-CoV-2 S) and neutralizing titers against Wuhan D614G, Delta and Omicron in a pseudovirus neutralization assay.

Sera of the majority of unvaccinated convalescents did not effectively neutralize Delta and Omicron (4/29, 13.8% and 19/29, 65.5%, resp.). Neutralizing titers against Wuhan D614G, Delta and Omicron were significantly higher in vaccinated compared to unvaccinated convalescents (p<0.0001) with 11.1, 15.3 and 60-fold higher geometric mean of 50%-neutralizing titers (NT50) in vaccinated compared to unvaccinated convalescents. The increase in neutralizing titers was already achieved by one vaccination dose. Neutralizing titers were highest in the first 3 months after vaccination. Concentrations of anti-S antibodies in the serological assays anti-SARS-CoV-2 QuantiVac-ELISA (IgG) and Elecsys Anti-SARS-CoV-2 S predict neutralization capacity against Wuhan D614G, Delta and Omicron. While Wuhan D614G was neutralized in-vitro by Bamlanivimab, Casirivimab and Imdevimab, Omicron was resistant to these monoclonal antibodies.

Conclusions These findings confirm substantial immune evasion of Delta and Omicron which can be overcome by vaccination of convalescents. This informs strategies for choosing of plasma donors in COVID-19 convalescent plasma programs that shall select specifically vaccinated convalescents with very high titers of anti-S antibodies.

Competing Interest Statement

I have read the journal's policy and the authors of this manuscript have the following competing interests: B.J., S.K., R.L., R.M., P.W., M.S., H.K. and H.S. are employees of a blood transfusion service collecting plasma including convalescent plasma.

Funding Statement

The clinical trials COVIC-19 (EudraCT 021-006621-22) is supported by the Bundesministerium fuer Bildung und Forschung (German Federal Ministry of Education and Research)(www.bmbf.de) and the randomized clinical trial CAPSID (EudraCT including the preparation of convalescent plasma units was supported by the Bundesministerium fuer Gesundheit (German Federal Ministry of Health)(www.bundesgesundheitsministerium.de). H.S., J.M. and H.K. acknowledge funding from the Ministry for Science, Research and the Arts of Baden-Wuerttemberg, Germany (COVID-19 Sonderfoerderlinie, CORE Project)(mwk.baden-wuerttemberg.de). HS acknowledges funding by the European Commission (HORIZON2020 Project SUPPORT-E, no. 101015756). J.M. further acknowledges funding by EU?s Horizon 2020 research and innovation programme (Fight-nCoV, 101003555)(ec.europa.eu). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The studies were approved by the Ethical Committee of University of Ulm and Ethical Committee II, Heidelberg University

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All relevant data are within the manuscript and its Supporting Information files.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted January 17, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
SARS-CoV-2 vaccination of convalescents boosts neutralization capacity against SARS-CoV-2 Delta and Omicron that can be predicted by anti-S antibody concentrations in serological assays
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
SARS-CoV-2 vaccination of convalescents boosts neutralization capacity against SARS-CoV-2 Delta and Omicron that can be predicted by anti-S antibody concentrations in serological assays
Alina Seidel, Bernd Jahrsdörfer, Sixten Körper, Dan Albers, Pascal von Maltitz, Rebecca Müller, Ramin Lotfi, Patrick Wuchter, Harald Klüter, Michael Schmidt, Jan Münch, Hubert Schrezenmeier
medRxiv 2022.01.17.22269201; doi: https://doi.org/10.1101/2022.01.17.22269201
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
SARS-CoV-2 vaccination of convalescents boosts neutralization capacity against SARS-CoV-2 Delta and Omicron that can be predicted by anti-S antibody concentrations in serological assays
Alina Seidel, Bernd Jahrsdörfer, Sixten Körper, Dan Albers, Pascal von Maltitz, Rebecca Müller, Ramin Lotfi, Patrick Wuchter, Harald Klüter, Michael Schmidt, Jan Münch, Hubert Schrezenmeier
medRxiv 2022.01.17.22269201; doi: https://doi.org/10.1101/2022.01.17.22269201

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (430)
  • Allergy and Immunology (756)
  • Anesthesia (221)
  • Cardiovascular Medicine (3290)
  • Dentistry and Oral Medicine (364)
  • Dermatology (278)
  • Emergency Medicine (479)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1170)
  • Epidemiology (13368)
  • Forensic Medicine (19)
  • Gastroenterology (898)
  • Genetic and Genomic Medicine (5153)
  • Geriatric Medicine (482)
  • Health Economics (782)
  • Health Informatics (3264)
  • Health Policy (1140)
  • Health Systems and Quality Improvement (1190)
  • Hematology (430)
  • HIV/AIDS (1017)
  • Infectious Diseases (except HIV/AIDS) (14624)
  • Intensive Care and Critical Care Medicine (913)
  • Medical Education (476)
  • Medical Ethics (127)
  • Nephrology (522)
  • Neurology (4922)
  • Nursing (262)
  • Nutrition (730)
  • Obstetrics and Gynecology (883)
  • Occupational and Environmental Health (795)
  • Oncology (2522)
  • Ophthalmology (723)
  • Orthopedics (281)
  • Otolaryngology (347)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (543)
  • Pediatrics (1302)
  • Pharmacology and Therapeutics (550)
  • Primary Care Research (557)
  • Psychiatry and Clinical Psychology (4208)
  • Public and Global Health (7501)
  • Radiology and Imaging (1705)
  • Rehabilitation Medicine and Physical Therapy (1012)
  • Respiratory Medicine (980)
  • Rheumatology (479)
  • Sexual and Reproductive Health (497)
  • Sports Medicine (424)
  • Surgery (548)
  • Toxicology (72)
  • Transplantation (236)
  • Urology (205)